You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 18, 2026

Claims for Patent: 9,814,691

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,814,691

Title:	Fumarate ester pharmaceutical compositions
Abstract:	Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising fumarate esters are described.
Inventor(s):	Tatyana Dyakonov, Sunil Agnihotri, Aqeel A. Fatmi
Assignee:	Banner Life Sciences LLC
Application Number:	US15/358,305
Patent Claims:	1. A method for treating or reducing symptoms of multiple sclerosis in a subject comprising administering to the subject an oral immediate release pharmaceutical composition comprising one or more fumarate esters in a single phase non-aqueous vehicle. 2. The method of claim 1, wherein the fumarate ester comprises dimethyl fumarate, monomethyl fumarate, or a combination thereof. 3. The method of claim 1, wherein the fumarate ester comprises dimethyl fumarate. 4. The method of claim 1, wherein the fumarate ester comprises monomethyl fumarate. 5. The method of claim 1, wherein the composition further comprises polyvinylpyrrolidone, polyoxyl 40 hydrogenated castor oil, and lactic acid. 6. The method of claim 1, wherein the composition comprises about 25% to about 50% of one or more fumarate esters and about 40% to about 54% of mono- and di-glycerides. 7. The method of claim 6, wherein the composition further comprises about 1% to about 10% polyvinylpyrrolidone; about 2% to about 10% polyoxyl 40 hydrogenated castor oil; and about 5% lactic acid. 8. The method of claim 1, wherein the composition comprises about 60 mg to about 200 mg of one or more fumarate esters. 9. The method of claim 1, wherein about 120 mg to about 400 mg of the fumarate ester is administered per day. 10. The method of claim 1, wherein two or more doses of the composition are administered at one time. 11. The method of claim 1, wherein the composition is encapsulated in an enteric soft capsule that provides delayed release of the fumarate ester. 12. A method for treating or reducing symptoms of multiple sclerosis in a subject comprising administering to the subject an oral immediate release pharmaceutical composition comprising about 60 mg to about 200 mg of a fumarate ester in a single phase non-aqueous vehicle. 13. The method of claim 12, wherein the fumarate ester comprises dimethyl fumarate, monomethyl fumarate, or a combination thereof. 14. The method of claim 12, wherein the fumarate ester comprises dimethyl fumarate. 15. The method of claim 12, wherein the fumarate ester comprises monomethyl fumarate. 16. The method of claim 12, wherein the composition further comprises, polyvinylpyrrolidone, polyoxyl 40 hydrogenated castor oil, and lactic acid. 17. The method of claim 12, wherein the composition comprises about 25% to about 50% of one or more fumarate esters and about 40% to about 54% of mono- and di-glycerides. 18. The method of claim 17, wherein the composition further comprises about 1% to about 10% polyvinylpyrrolidone; about 2% to about 10% polyoxyl 40 hydrogenated castor oil; and about 5% lactic acid. 19. The method of claim 12, wherein about 120 mg to about 400 mg of the fumarate ester is administered per day. 20. The method of claim 12, wherein two or more doses of the pharmaceutical composition are administered at one time. 21. The method of claim 12, wherein the composition is encapsulated in an enteric soft capsule that provides delayed release of the fumarate ester. 22. A method for treating or reducing symptoms of multiple sclerosis in a subject comprising administering to the subject an immediate release oral pharmaceutical composition comprising about 60 mg to about 200 mg of dimethyl fumarate, monomethyl fumarate, or a combination thereof in a single phase non-aqueous liquid vehicle. 23. The method of claim 22, wherein the composition further comprises polyvinylpyrrolidone, polyoxyl 40 hydrogenated castor oil, and lactic acid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.